Uncategorized – Page 2

New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities

2 days ago talkbio0Tagged 1964, Changing, civil, Civil Rights Act, Condition, Diversity, federal, Israeli (population group), NIH, Policy, Protections, recipients, United States National Institutes of Health

United States National Institutes of Health, recipients, NIH, Policy, Diversity, Changing, Condition, civil, federal, civil, protections, recipients, Israeli (population group), Civil Rights Act, 1964

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

2 days ago talkbio0Tagged Approved, competition, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Novo, Obesity, Oral cavity, Pressure- physical agent, semaglutide, United States Food and Drug Administration

Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration

Navigating Trumps tariffs for pharma

2 days ago talkbio0Tagged Biomechanical compliance, Financial cost, HTS, Import, tariffs

Import, Biomechanical compliance, Financial cost, tariffs, HTS

Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal

2 days ago talkbio0Tagged Keytruda, Metastatic to, Overall Survival, Triple Negative Breast Neoplasms, Trodelvy

Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival

Dupixent notches seventh disease approval with urticaria nod

2 days ago talkbio0Tagged Approved, Chronic Spontaneous Urticaria, Dupixent, seventh, United States Food and Drug Administration, Urticaria

Dupixent, Chronic Spontaneous Urticaria, Approved, Urticaria, United States Food and Drug Administration, seventh

Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies

2 days ago talkbio0Tagged Aortic Valve Insufficiency, Dosage Forms, Drug Discovery, Jorna, RNA

Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies

AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer

3 days ago talkbio0Tagged Antibodies, Antibody-Drug Conjugates, AstraZeneca, Daiichi, deruxtecan-nxki, Enhertu, fam-trastuzumab, first-line therapy, HER2-positive metastatic breast cancer, pertuzumab, Progression-Free Survival, Sankyo

Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab

Immunovant Refines R&D Strategy with New Leadership

3 days ago talkbio0Tagged Changing, Focal, Immunovant, Leadership, Roivant

Immunovant, Roivant, R&D Focus, Leadership Changes, IMVT-1402

Chinese CRO GemPharmatech expands in San Diego as industry weighs FDA’s animal testing shift

3 days ago talkbio0Tagged Animal Testing, Contract Research Organization, expansion, GemPharmatech, Industry, mouse models, San Diego, United States Food and Drug Administration

United States Food and Drug Administration, GemPharmatech, Contract Research Organization, San Diego, Animal Testing, mouse models, expansion, Industry

FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD

3 days ago talkbio0Tagged Age related macular degeneration, Diabetic Retinopathy, dosing, Extension, Eylea HD, Interval, Regeneron, Rejection, United States Food and Drug Administration

United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy